Table 3 Univariate and multivariate survival analysis of progression-free survival.

Age

<67/≥67

1.22

0.85–1.75

Sex

Male/female

1.74

0.91–3.33

Tumour location

Ut/Mt, Lt

1.08

0.66–1.76

Chemotherapy regimen

Others/DCF

1.31

0.89–1.92

cT

3–4/0–2

1.99

1.28–3.11

1.09

0.61–1.96

0.76

0.95

0.52–1.71

0.85

cN

1–3/0

1.48

0.96–2.29

SUVmax pre

≥12.79/<12.79

1.36

0.95–1.96

SUVmax post

≥4.52/<4.52

2.33

1.62–3.36

1.65

0.83–3.28

0.15

1.58

0.77–3.26

0.21

SUVmax reduction rate

<60% />60%

1.75

1.21–2.53

1.66

0.88–3.12

0.12

1.53

0.81–2.90

0.19

MTV pre

≥22.8/<22.8

1.64

1.14–2.36

1.07

0.67–1.71

0.78

1.06

0.66–1.69

0.82

MTV post

≥3.20/<3.20

1.81

1.25–2.60

0.51

0.12–2.20

0.37

0.51

0.12–2.23

0.37

MTV reduction rate

<80%/>80%

1.70

1.18–2.45

0.51

0.22–1.17

0.11

0.49

0.22–1.14

0.097

TLG pre

≥42.2/<42.2

1.81

1.16–2.82

1.91

0.89–4.08

0.096

1.74

0.81–3.71

0.15

TLG post

≥11.2/<11.2

1.95

1.35–2.81

1.37

0.31–6.00

0.67

1.07

0.24–4.71

0.93

TLG reduction rate

<80%/>80%

2.04

1.41–2.97

2.58

1.16–5.73

0.020

2.51

1.14–5.51

0.022

Number of PET-positive LNs before NACT

≥2 /0–1

1.66

1.15–2.39

1.37

0.90–2.09

0.14

1.29

0.84–1.99

0.24

Number of PET-positive LNs after NACT

≥2/0–1

2.32

1.48–3.65

1.79

1.04–3.08

0.035

1.68

0.97–2.92

0.063

Postoperative complication^a

III–V/0–II

1.28

0.87–1.89

pT

3–4/0–2

2.39

1.65–3.45

1.54

0.97–2.46

0.069

pN

1–3/0

2.44

1.57–3.80

1.96

1.24–3.10

0.004

Histological grade

0–1a/1b-3

1.71

1.18–2.47

1.34

0.90–1.99

0.16